Abstract Details

Title Lecanemab Real-world Treatment Outcomes from a Geriatric Medicine Clinical Practice: A Retrospective Dementia Clinic Case Series Review in Early Alzheimer’s Disease

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 12-007

Objective To report real-world data on patients with early Alzheimer’s disease (AD) treated with lecanemab in our geriatric clinical practice.

Background Lecanemab, a monoclonal antibody binding with high affinity to protofibrils of Aβ-protein, significantly reduced amyloid biomarkers and slowed clinical decline on multiple measures of cognition and function for up to 48 months in the phase 3 Clarity AD trial.

Design/Methods This retrospective case series evaluated individuals with early AD administered lecanemab treatment over the past 28 months at Bristol Health. Data collection included patient characteristics, efficacy assessments (Montreal Cognitive Assessment [MoCA], Clinical Dementia Rating Scale Sum of Boxes [CDR-SB] and global score [CDR-global], and Functional Activities Questionnaire [FAQ]). Feedback on experience with subcutaneous and intravenous lecanemab were collected via a survey.

Results Overall, 53 individuals with early AD (mild AD:33; mild cognitive impairment:20) treated with lecanemab for a mean duration of 10 months were included. Mean time from diagnosis to treatment of 5.8 months, decreasing over time (mean time 2023: 9.7 months; 2024: 5.5 months; 2025: 3.6 months). For the 26 patients with MoCA baseline and post-baseline scores, 10 patients had improved scores and 10 had stable scores (within 10% of baseline). Among the 17 patients with CDR-SB baseline and post-baseline scores, 3 patients had improved scores and 7 had stable scores. Five of 13 patients who had post-baseline FAQ assessments had improved or remained stable. CDR global scores were improved or stable for 16/18 patients (improved:1; stable:15). Five (9.4%) ARIA-E cases (1 symptomatic; 4 resolved) and six (11.3%) ARIA-H cases (1 symptomatic; 4/5 ARIA-H were isolated) were observed. Infusion related reactions occurred in 5 patients (9.4%). Patients reported feeling ‘very satisfied’ or ‘satisfied’ with lecanemab treatment.

Conclusions Lecanemab efficacy and safety profile was similar to that observed in clinical studies in our real-world geriatric clinical practice setting.

Authors/Disclosures
Margarita Reyes, MD PRESENTER	Dr. Reyes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Reyes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly.

��ɫ��

��ɫ��